JAK2 and hyperlipidemia: Older age (odds ratio-OR 1.19, 95% confidence interval-CI 1.06–1.33) and higher body weight (OR = 1.15, 95% CI 1.06–1.25) were independently associated with the presence of sOA, whereas cytoreductive treatment (OR = 0.07, 95% CI 0.006–0.86) had protective properties; sex, MF phenotype, presence of JAK2 mutation, arterial hypertension, hyperlipidemia, smoking, CKD, and serum uric acid lost their independent associations with sOA in the multivariate analysis.